Navigation Links
Phase III Study Shows Once-Daily NVA237 is Superior to Placebo and Similar to Tiotropium in Improving Lung Function in COPD
Date:6/30/2011

primary endpoint by demonstrating superior 24-hour bronchodilation to placeboat 12 weeks measured by trough FEV1 (i.e. forced expiratory volume in one second), a standard measure of lung function[1]. NVA237 was delivered using the Concept1® device, a single-dose dry-powder inhaler.

Key secondary endpoints were improvement in breathlessness assessed using the Transition Dyspnea Index (TDI) at 26 weeks, and improved quality of life as measured by the St George's Respiratory Questionnaire (SGRQ) at 52 weeks. Important secondary endpoints were time to first COPD exacerbation and use of rescue medication during 52 weeks of treatment. The study met all of these endpoints.

The GLOW2 study also showed that NVA237 was well-tolerated with a similar incidence of adverse events for patients treated with NVA237, placebo and open-label tiotropium.

GLOW2 was a 52-week double-blind, placebo-controlled, parallel-group study involving 1,066 patients to assess the efficacy, safety and tolerability of NVA237 in patients with COPD. Patients were randomized into three treatment arms receiving either once-daily NVA237 50 mcg, placebo, or once-daily open-label tiotropium 18 mcg. They were also permitted to use COPD background therapy and rescue medication.

In April 2011 Novartis announced results from the first Phase III clinical trial with NVA237. The pivotal double-blind 26-week GLOW1 study met its primary endpoint by demonstrating superior bronchodilation to placebo at 12 weeks measured by trough FEV1 (p<0.001). The incidence of adverse events was similar in NVA237-treated patients and in those receiving placebo. Further data from GLOW1 will be presented at the European Respiratory Society congress in Amsterdam in September 2011.

NVA237 was licensed to Novartis in April 2005 by Sosei and its co-development partner Vectura.  Novartis intends to launch NVA237 in 2012 as a once-daily monotherapy for COPD.  The first launch for Q
'/>"/>

SOURCE Sosei Group Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. DNA Medicine Institute Awarded Two Phase III SBIR NASA Contracts for Its rHEALTH Sensor
2. Phase I of the Swedish/Issaquah Medical Center Campus to Open in July
3. The Lancet Publishes Data from Protege, MacroGenics Phase 3 Clinical Study of Teplizumab in Type 1 Diabetes Patients
4. Morphotek®, Inc. Announces Initiation of Farletuzumab Phase II Study in First-Line Treatment of Non-Small Cell Lung Cancer
5. Palatin Technologies, Inc. Initiates Enrollment in Phase 2b Trial With Bremelanotide in Women With Female Sexual Dysfunction
6. Cardium Announces Plans to Acquire Transdel Pharmaceuticals Phase 3 Topical Analgesic and Cosmeceutical Business Assets
7. Glycotex, Inc. Releases Final Phase II Clinical Trials Results in the Clinicaltrials.gov Database and Announces the Results of the Mechanism of Action Study for its Product Candidate GLYC-101
8. Ampio Pharmaceuticals, Inc. Releases Results From Phase III Clinical Trial of Zertane™ for the Treatment of Premature Ejaculation (PE), the Most Prevalent Form of Male Sexual Dysfunction
9. Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
10. Once-Monthly Exenatide Improved Glucose Control in Patients with Type 2 Diabetes: Phase 2 Study Results Presented at ADA 2011
11. New Phase 2 Data Published in New England Journal of Medicine Show Bardoxolone Methyl Sustained Improvement in Measure of Kidney Function (eGFR) Over 52 Weeks in Patients With Moderate to Severe Chronic Kidney Disease and Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... N.J. , May 4, 2015 ... immunotherapy company commercializing its CytoSorb® extracorporeal cytokine adsorber ... multiple countries worldwide, will report Q1 2015 financial ... 11, 2015.  CytoSorbents, management will ... that will recount both operational and financial progress ...
(Date:5/4/2015)... , May 4, 2015 /PRNewswire/ - YOLO ... the manufacturing and distribution of medical and aesthetic ... market clearance for YOLO,s new generation body contouring ... has completed its second-generation low-level laser device for ... advancements to our patented technology while continuing to ...
(Date:5/4/2015)... May 4, 2015 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or ... notification from the Food and Drug Administration ("FDA" or the ... March 31, 2015, has been placed on clinical hold pending ... related to the stability of the drug substance and drug ... The Company had sought approval of their IND application ...
Breaking Medicine Technology:CytoSorbents to Report Q1 2015 Operating and Financial Results 2CytoSorbents to Report Q1 2015 Operating and Financial Results 3YOLO Medical Inc. receives FDA clearance for body contouring laser 2ESSA Pharma Inc. Receives FDA Response on IND Application 2ESSA Pharma Inc. Receives FDA Response on IND Application 3ESSA Pharma Inc. Receives FDA Response on IND Application 4
... HONG KONG, Sept. 20, 2011 /PRNewswire-Asia/ -- Golden ... subsidiaries collectively as the "Group," - 801.HK; 910801.TW), a ... of 2.0% interest in FunTalk China Holdings Limited, the ... the Group,s effective interest in FunTalk China will be ...
... NEW YORK, September 20, 2011 Preetha ... the United Nations Summit at New York held by ... of Non-Communicable Diseases. Non-communicable diseases, such as ... disease, account for more than 63 percent of all ...
Cached Medicine Technology:Golden Meditech Disposes of 2.0% Stake in FunTalk China for US$15 Million 2Preetha Reddy, Managing Director, Apollo Hospitals Invited to United Nations Summit on NCDs 2
(Date:5/4/2015)... Dr. Benjamin Stong of Kalos Facial Plastic ... non-surgical double-chin eliminator. Dr. Stong is double board ... to offer Kybella treatments . The FDA recently ... the chin, promising to safely dissolve fat deposits and ... sought immediate solutions for their double chin were forced ...
(Date:5/4/2015)... Dr. Richard Champagne, DMD, MAGD is pleased to ... America’s Best Dentist Award, given by the National Consumer ... dentist is a reflection of his vast experience in ... for his patients. , Each year, the National Consumer ... field. These nominees are dentists who have exceptionally high ...
(Date:5/4/2015)... For partners who’d like to become parents, ... Astroglide TTC™ (Trying to Conceive) . Unlike traditional lubricants ... Astroglide TTC™ is specially formulated to provide a better ... for Disease Control, an average of one in ... a pregnancy, and over 7.4 million women ...
(Date:5/4/2015)... Washington, DC (PRWEB) May 04, 2015 ... (ACE) has just released the first-ever congenital ... Congenital Cardiac Catheterization Laboratory (PCCL) accreditation. Driven ... CHD standards are a comprehensive review of ... with congenital heart disease. , “The ACE ...
(Date:5/4/2015)... California (PRWEB) May 04, 2015 Sara ... a physician practice management firm in Los Angeles associated ... today the patent-pending status of The Sara Soulati Health ... Soulati in 2010, is a lifestyle modification and disease ... April 2015 to the U. S. Patents and Trademarks ...
Breaking Medicine News(10 mins):Health News:Facial Plastic Surgeon First in Atlanta To Offer Kybella Treatments To Reduce Chin Fat 2Health News:New Jersey Dentist Dr. Richard Champagne Nominated for America’s Best Dentist Award 2Health News:Astroglide Announces the Birth of Its New Baby: Astroglide TTC 2Health News:Astroglide Announces the Birth of Its New Baby: Astroglide TTC 3Health News:Accreditation for Cardiovascular Excellence (ACE) Publishes New Standards for Pediatric and Adult Congenital Cardiac Catheterization Laboratories 2Health News:CEO Sara Soulati Announces Patent-Pending Designation For The Sara Soulati Health For Life Program 2
... tests separately predict the likelihood that a patient,s breast ... the cancer,s vulnerability to chemotherapy or hormone therapy, researchers ... Center report at the first American Society of Clinical ... Francisco. , Each predictor - of prognosis, of ...
... to headline Boston forums, BOSTON, Sept. 7 ... and former Republican,Governor Mike Huckabee (AR) will address ... 2007. (Logo: http://www.newscom.com/cgi-bin/prnh/20070209/NYF043LOGO ) ... AARP,s annual,member event. The candidates will address AARP,s ...
... PA, Sept. 7 /PRNewswire-FirstCall/ - MDS Pharma,Services, a ... has won the Good Clinical Practice Journal (GCPj) ... access to new medicines. This,award is one of ... year to,recognize excellence in clinical research. MDS Pharma ...
... hours of instruction improved relationships with patients, study claims ... evidence suggests that a bit of theatrics can help ... on the experience of a small group of internal ... workshops and lectures led by university theater professors. , ...
... October 16, 2007, SUNNYVALE, Calif., Sept. 7 ... has set October 16, 2007, as the,date of the ... with a wholly owned subsidiary of Medtronic. The ... Time, at,Kyphon,s corporate headquarters located at 1221 Crossman Avenue, ...
... LifeQuest World,Corporation (formerly PhytoLabs Inc.) announced today that the ... contest to allow the,public to participate in choosing a ... 30, 2007. The company was unable to use any ... prize of a trip for two to,Las Vegas was ...
Cached Medicine News:Health News:Microarray provides 3 genomic guides to breast cancer treatment decisions 2Health News:Microarray provides 3 genomic guides to breast cancer treatment decisions 3Health News:Microarray provides 3 genomic guides to breast cancer treatment decisions 4Health News:Presidential Candidates Address Health, Financial Security at AARP's Life@50+ 2Health News:MDS Pharma Services Wins Award for Management of Global Malaria Trial 2Health News:Theater Classes Help Docs' Bedside Manners 2Health News:Theater Classes Help Docs' Bedside Manners 3Health News:Kyphon Announces Special Meeting Date to Vote on Proposed Medtronic Merger 2Health News:Kyphon Announces Special Meeting Date to Vote on Proposed Medtronic Merger 3Health News:LifeQuest Announces End of Immunity Health Challenge Contest 2
Duckbill. 3.5 mm tip. Light curve....
4 mm x 9 mm tip....
6 mm wide tip. Gentle tapered blade. Designated most popular model or size....
9 mm wide tip. 35 mm from angle to tip....
Medicine Products: